Editor’s Choice: Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant

Editor’s Choice: A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer

Hosted by:
Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology

Featuring:
William Cliby, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Chiara Ainio, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Oliver Zivanovic, Clinic for Gynecology and Obstetrics, Heidelberg University Hospital, Heidelberg, Germany

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial

Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms

Editor’s Choice: Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology – A prospective randomized trial

Editorial: Relax - It’s evidence-based: The role of hypnosis in managing post-operative symptoms

Editor’s Choice: TROP2 expression and therapeutic targeting in uterine carcinosarcoma

Editorial: The search for new therapeutic options for uterine carcinosarcoma

Editor’s Choice: STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs

Editorial: Diverting ileostomy: An ounce of prevention, but when?

Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?

Hosted by:
Warner Huh, MD, Deputy Editor of Gynecologic Oncology
Featuring:
Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of America
Ramez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study

Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?

Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival

Editorial: Clinical trials are not the solution to inequities in cancer care